Paper Details

  1. Home
  2. Paper Details

Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis.

Author: BoxHelen, FeltonTimothy W, GoodwinJoanne, HopeWilliam W, JohnsonAdam, LivermoreJoanne, McEnteeLaura, WhalleySarah

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study describes the pharmacodynamics of isavuconazole, the active moiety of the novel triazole prodrug isavuconazonium sulfate, against Aspergillus fumigatus in a dynamic in vitro model of the human alveolus. The study found that isolates with higher MICs required higher AUCs to achieve maximal suppression of galactomannan, a marker of fungal burden. The AUC/MIC targets necessary to achieve 90% probability of galactomannan suppression of <1 were 11.40 and 11.20 for EUCAST and CLSI, respectively.
Paper Details　
Original Abstract of the Article :
Isavuconazonium sulfate is a novel triazole prodrug that has been recently approved for the treatment of invasive aspergillosis by the FDA. The active moiety (isavuconazole) has a broad spectrum of activity against many pathogenic fungi. This study utilized a dynamic in vitro model of the human alve...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704219/

データ提供：米国国立医学図書館（NLM）

Isavuconazole's Pharmacodynamics in Invasive Pulmonary Aspergillosis

Invasive pulmonary aspergillosis, like a desert sandstorm, can be a life-threatening fungal infection. This study investigates the pharmacodynamics of isavuconazole, a novel triazole antifungal agent, against Aspergillus fumigatus. The researchers utilized a dynamic in vitro model of the human alveolus to assess the antifungal activity of isavuconazole and determine the target values for its efficacy.

Understanding Isavuconazole's Activity

The study found that isavuconazole exhibited potent antifungal activity against both wild-type and azole-resistant isolates of Aspergillus fumigatus. This is like finding a powerful antidote in the desert, able to neutralize a dangerous threat. The researchers determined that higher isavuconazole concentrations were needed to achieve maximum suppression of fungal burden in isolates with higher minimum inhibitory concentrations (MICs). The AUC/MIC targets necessary to achieve 90% probability of galactomannan suppression were calculated, providing valuable information for optimizing isavuconazole therapy.

Optimizing Antifungal Therapy

This research provides valuable insights into the pharmacodynamics of isavuconazole and its potential for treating invasive pulmonary aspergillosis. This is like mapping a desert landscape, understanding the terrain and resources needed for a successful journey. The study highlights the importance of individualizing isavuconazole therapy based on the susceptibility of the infecting strain to ensure optimal treatment outcomes.

Dr.Camel's Conclusion

This study explores the pharmacodynamics of isavuconazole, a promising antifungal agent for treating invasive pulmonary aspergillosis. The study provides valuable insights into the drug's activity against different strains of Aspergillus fumigatus, suggesting the need for personalized therapy based on the susceptibility of the infecting strain. This research, like a camel navigating the desert with knowledge and adaptability, offers a path towards more effective and targeted treatment strategies for this challenging fungal infection.

Date :
  1. Date Completed 2016-10-07
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

26503648

DOI: Digital Object Identifier

PMC4704219

Related Literature

Article Analysis
・Effects of isavuconazonium
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.